Home > Clinical Trials
Check All Search

Saved trials

ACTIVE_NOT_RECRUITING
NCT04539938
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
70 Enrollment(s)
33 Study location(s)
INTERVENTIONAL (PHASE2)
HER2 Positive Breast Cancer
RECRUITING
NCT04482309
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
468 Enrollment(s)
123 Study location(s)
INTERVENTIONAL (PHASE2)
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer


Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
RECRUITING
NCT03424005
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
580 Enrollment(s)
39 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer
RECRUITING
NCT06928818
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
100 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Cancer of Breast


Trastuzumab Emtansine


Trastuzumab Deruxtecan
RECRUITING
NCT04686305
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
244 Enrollment(s)
80 Study location(s)
INTERVENTIONAL (PHASE1)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ACTIVE_NOT_RECRUITING
NCT06386263
HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
22 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Unresectable Breast Cancer


Metastatic Breast Cancer


HER2-low Expressing Breast Cancer


HER2-positive Breast Cancer
RECRUITING
NCT06324357
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
582 Enrollment(s)
47 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer


Metastatic Gastric Adenocarcinoma


Gastroesophageal Junction Adenocarcinoma


Esophageal Adenocarcinoma
RECRUITING
NCT02390752
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
54 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Neurofibroma, Plexiform


Precursor Cell Lymphoblastic Leukemia-Lymphoma


Leukemia, Promyelocytic, Acute


Sarcoma